E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Cough relating to lung cancer |
|
E.1.1.1 | Medical condition in easily understood language |
Cough relating to lung cancer |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 15.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025044 |
E.1.2 | Term | Lung cancer |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 15.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10011224 |
E.1.2 | Term | Cough |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1) Does Aprepitant alleviate cough in lung cancer patients? |
|
E.2.2 | Secondary objectives of the trial |
• To determine the effect of Aprepitant on cough-specific quality of life (MCLCS) scores for lung cancer patients. • To determine the effect of Aprepitant on Visual Analogue Scale (VAS) scores for lung cancer patients. • To determine whether biomarkers can predict cough severity. These may include IL-6, IL-8, IL-10 & TNF-α • To determine whether Aprepitant should be tested in a larger definitive study
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Patients willing and able to give consent for participation in the trial • Male or female aged 18 years or above • WHO PS 0-2 • Diagnosed with lung cancer • Able and willing to participate in and comply with the trial schedule • Persistent cough ≥ 4 weeks • Not on anticancer therapy • No anticancer therapy planned to commence for the duration of the trial participation
|
|
E.4 | Principal exclusion criteria |
• Received anticancer therapy within 4 weeks of trial entry • Receiving Aprepitant therapy • Presence of a RTI within last 4 weeks. • Previous adverse event to Aprepitant • Presence of constipation grade 2 or above (CTCAE v4) • Scheduled elective surgery or other procedures requiring sedation or general anaesthesia during trial period • Potentially fertile women of child-bearing age • Currently participating in another research trial involving an investigational product • Any other significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the trial or affect the patient’s ability to participate in the trial.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
A comparison of the change from baseline in cough count for Aprepitant versus placebo.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Cough Severity Visual Analogue Scale Score Manchester Cough in Lung Cancer Scale Score Preliminary toxicity profile of Aprepitant Biomarker Level |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
all analysed on Day 3 and Day 9 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
predictive cough biomarker investigation |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |